Achilles Therapeutics PLC ADR
$ 1.48
0.00%
12 Mar - close price
- Market Cap 63,220,000 USD
- Current Price $ 1.48
- High / Low $ 1.48 / 1.48
- Stock P/E N/A
- Book Value 2.51
- EPS -1.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.52 %
- 52 Week High 1.51
- 52 Week Low 1.42
About
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$0.50
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-11 | 2024-08-14 | 2024-05-08 | 2024-02-29 | 2023-11-13 | 2023-08-04 | 2023-05-10 | 2023-03-07 | 2022-11-08 | 2022-08-09 | 2022-05-09 | 2022-03-01 |
| Reported EPS | -0.48 | -0.41 | -0.3 | -0.46 | -0.42 | -0.42 | -0.44 | -0.61 | -0.32 | -0.44 | -0.45 | -0.45 |
| Estimated EPS | -0.48 | -0.41 | -0.46 | -0.14 | -0.4 | -0.42 | -0.4 | -0.41 | -0.55 | -0.56 | -0.5 | -0.41 |
| Surprise | 0 | 0 | 0.16 | -0.32 | -0.02 | 0 | -0.04 | -0.2 | 0.23 | 0.12 | 0.05 | -0.04 |
| Surprise Percentage | 0% | 0% | 34.7826% | -228.5714% | -5% | 0% | -10% | -48.7805% | 41.8182% | 21.4286% | 10% | -9.7561% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHL
2025-12-21 14:09:35
Achilles Therapeutics has appointed Dr. Alena Gros and Dr. Ben Creelan to its Scientific Advisory Board. These internationally recognized experts bring extensive experience in cancer immunology and immunotherapy, which will be invaluable as the company advances its clinical development of personalized clonal-neoantigen T cell therapies for solid tumors. They will provide scientific and clinical guidance, particularly for ongoing trials in non-small cell lung cancer and melanoma.
2025-04-25 10:52:20
Achilles Therapeutics (ACHL) is a clinical-stage biopharmaceutical company that developed AI-powered precision T cell therapies targeting clonal neoantigens for solid tumors. The company, which utilized its PELEUS bioinformatics platform and had ongoing Phase I/IIa trials, has now announced a voluntary delisting from Nasdaq and deregistration from the SEC, in connection with a planned voluntary liquidation. This decision followed strategic shifts, including discontinuing clinical programs and exploring asset sales, marking a significant change in its corporate strategy.
2025-02-28 08:53:36
Achilles Therapeutics plc (NASDAQ: ACHL) has announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister its ADSs from the SEC. This decision is in connection with a contemplated members' voluntary liquidation, for which shareholder approval will be sought on March 20, 2025, which is also expected to be the last trading day for the company's common stock on Nasdaq.
2025-01-06 15:11:21
Achilles Therapeutics (ACHL) announced the resignation of three Board members, Julie O’Neill, Michael Giordano, and Bernhard Ehmer, effective December 31, 2024. This action is part of a planned reduction in board size and is not attributed to any disagreements, indicating a strategic realignment within the biotechnology company. Achilles Therapeutics focuses on developing precision T cell therapies for cancer.
2024-11-19 12:00:00
Achilles Therapeutics plc announced its approval to transfer its American Depositary Shares (ADSs) listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024. This transfer allows the company an additional 180 days to regain compliance with Nasdaq's minimum bid price requirement of US$1.00 per share. The company's ADSs will continue to trade under the symbol "ACHL".
2024-09-19 07:00:00
Achilles Therapeutics announced the discontinuation of its TIL-based cNeT program and will refocus its strategy on exploring engagements with third parties for alternative modalities to target clonal neoantigens. The company has engaged BofA Securities to advise on value-maximizing strategies and is implementing a workforce reduction and cost-cutting measures, while retaining $95.1 million in cash and cash equivalents as of June 30, 2024. Achilles remains committed to supporting employees through this transition and aims to leverage its assets and technology platforms to drive effective treatments and shareholder value.
